Search Results 661-670 of 17201 for ibd

  1. Vedolizumab Subcutaneous Long-Term Open-Label Extension Study - Mayo Clinic

    Surgical intervention for IBD during or after participation in Study MLN0002SC-3027 or MLN0002SC-3031, or at any time during this study. Chronic or severe ...

  2. Academics - Find a Program at Mayo Clinic College of Medicine & Science

    Gastroenterology, Inflammatory Bowel Disease Fellowship (Minnesota). Type: Fellowship; Duration: 1 year; School: Graduate Medical ...

  3. Health & Wellness - Page 94 of 810 - Mayo Clinic News Network

    Inflammatory bowel disease (IBD) is a chronic inflammation of the digestive tract. It includes conditions such as ulcerative colitis and Crohn's disease ...

  4. Featured News - Page 491 of 639

    Inflammatory bowel disease (IBD) is a chronic inflammation of the digestive tract. It includes conditions such as ulcerative colitis and Crohn's disease. People ...

  5. Publications - Search Publications by Mayo Clinic Authors - Mayo Clinic Research

    Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. Kabbani TA ...

  6. Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease - Mayo Clinic

    ... inflammatory bowel disease. In combination with medical therapies, surgical management of perianal fistulas is important for both infection control and ...

  7. Infliximab-Qbtx (Intravenous Route) Description and Brand Names - Mayo Clinic

    Infliximab-qbtx injection is used to reduce the symptoms of moderate-to-severely active Crohn's disease and ulcerative colitis in adults and children who have ...

  8. Study of GS-5290 in Participants With Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  10. Survey examines attitudes about ESG from providers around the world - Mayo Clinic

    Examining the use of endoscopic bariatric therapy in patients with IBD. MAC-20527800. Medical Professionals; Survey examines attitudes about ESG from providers ...